<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01471145</url>
  </required_header>
  <id_info>
    <org_study_id>60-60600-97-301</org_study_id>
    <secondary_id>2011-001890-15</secondary_id>
    <nct_id>NCT01471145</nct_id>
  </id_info>
  <brief_title>Depot Naltrexone Mechanism of Action in Heroin Dependent Patients Using fMRI and SPECT</brief_title>
  <acronym>XRNT</acronym>
  <official_title>Feasibility, Mechanism of Action and Potential Side Effects of Extended Release Depot Naltrexone in Opioid Dependent Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alkermes, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this project is to study brain functions of 20 heroin addicts (compared to brain
      functions of 20 healthy controls) just before and during a three month extended release
      naltrexone treatment using functional MRI and dopamine transporter SPECT.

      The following hypotheses are tested:

        -  XRNT modulates the fMRI response to drug cues in predetermined brain regions.

        -  The expression of striatal transporters (assessed with SPECT) will decrease after a
           three-month course of extended release naltrexone
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heroin dependence is a quintessential international health problem, with a significant
      prevalence. Drug free treatments, including pharmacologically supported interventions using
      oral naltrexone, have not been very successful, mainly due to low compliance. The recent
      introduction of Vivitrol®, consisting of monthly injections, may create new opportunities.
      Vivitrol® is an innovative treatment delivery method that blocks the rewarding effects of
      heroin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brain functions</measure>
    <time_frame>3 months</time_frame>
    <description>Brain functions of 20 heroin addicts just before and during a three month extended release naltrexone treatment using both functional MRI and dopamine transporter SPECT, compared to brain functions of 20 healthy controls.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility and potential efficacy</measure>
    <time_frame>3 months</time_frame>
    <description>The feasibility and potential efficacy of extended release naltrexone in a pilot sample of 20 Dutch heroin addicts in terms of (a) the percentage of patients that actually starts treatment when invited and (b) the percentage of 3 months retention.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Opioid-Related Disorders</condition>
  <condition>Heroin Dependence</condition>
  <arm_group>
    <arm_group_label>Depot Naltrexone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
    <description>naltrexone for extended-release injectable suspension, 380 mg/vial, every 4 weeks or once a month</description>
    <arm_group_label>Depot Naltrexone</arm_group_label>
    <other_name>Vivitrol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Heroin dependent patients: have a diagnosis of opioid dependence according to DSM-IV
             criteria, heroin as primary drug of abuse and inhalation as primary route of
             administration.

          -  Healthy controls: no diagnosis of substance dependence, no current psychotropic
             medication. Care will be taken to match controls for gender, age, smoking status, IQ
             and handedness.

        Exclusion Criteria:

          -  Age below 18 or over 55

          -  Medical contraindications for XRNT or MRI (Langleben 2006; Langleben, Ruparel et al.
             2008). Briefly, the former include candidates with known hypersensitivity to
             naltrexone,PLG (poly-lactide-coglycolide), carboxymethylcellulose, or any other
             components of the Vivitrol® diluent, hepatic or renal disease, chronic pain syndromes,
             female subjects who are pregnant or lactating, or are of child bearing potential and
             are not using an acceptable method of birth control. MRI contraindications include
             chronic medical (neurological, cardiovascular, infectious, metabolic, etc) conditions
             that may affect the brain morphology and/or activity and indwelling foreign metallic
             or magnetically sensitive objects and devices, such as shrapnel, pacemakers,
             orthopaedic fixation devices or vascular stents

          -  Presence of disorders precluding normal perception of visual and auditory stimuli,
             such as color blindness, deafness, severe myopia, etc.

          -  Patients with a history of or current psychosis or current major depressive disorder
             with suicidal ideation

          -  Patients who are being treated under forced treatment conditions

          -  History or evidence of disorders that may affect cerebral function or circulation,
             such as diabetes and other metabolic disorders, encephalopathy, cardiovascular or
             cerebrovascular disease, history of head trauma with depressed skull fracture or
             prolonged loss of consciousness and history of brain surgery

          -  Female subjects: women who are pregnant or breast-feeding

          -  Current psychotropic medication

          -  Use of any prescription medications that could affect alertness or the circulatory
             system

          -  IQ &lt; 70

          -  Naltrexone use within the past 6 months

          -  Baseline aspartate aminotransferase or alanine aminotransferase more than three times
             the upper limit of normal

          -  Patients with no intention to be opioid-free for a minimum of 7 days before starting
             XRNT treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wim van den Brink, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>P.O. Box 22660</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Cornish JW, Metzger D, Woody GE, Wilson D, McLellan AT, Vandergrift B, O'Brien CP. Naltrexone pharmacotherapy for opioid dependent federal probationers. J Subst Abuse Treat. 1997 Nov-Dec;14(6):529-34.</citation>
    <PMID>9437624</PMID>
  </reference>
  <reference>
    <citation>de Geus EJ, van't Ent D, Wolfensberger SP, Heutink P, Hoogendijk WJ, Boomsma DI, Veltman DJ. Intrapair differences in hippocampal volume in monozygotic twins discordant for the risk for anxiety and depression. Biol Psychiatry. 2007 May 1;61(9):1062-71. Epub 2006 Nov 29.</citation>
    <PMID>17137562</PMID>
  </reference>
  <reference>
    <citation>Knutson B, Westdorp A, Kaiser E, Hommer D. FMRI visualization of brain activity during a monetary incentive delay task. Neuroimage. 2000 Jul;12(1):20-7.</citation>
    <PMID>10875899</PMID>
  </reference>
  <reference>
    <citation>Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011 Apr 30;377(9776):1506-13. doi: 10.1016/S0140-6736(11)60358-9.</citation>
    <PMID>21529928</PMID>
  </reference>
  <reference>
    <citation>Langleben DD, Ruparel K, Elman I, Busch-Winokur S, Pratiwadi R, Loughead J, O'Brien CP, Childress AR. Acute effect of methadone maintenance dose on brain FMRI response to heroin-related cues. Am J Psychiatry. 2008 Mar;165(3):390-4. Epub 2007 Dec 3.</citation>
    <PMID>18056224</PMID>
  </reference>
  <reference>
    <citation>Lobmaier P, Kornør H, Kunøe N, Bjørndal A. Sustained-release naltrexone for opioid dependence. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006140. doi: 10.1002/14651858.CD006140.pub2. Review.</citation>
    <PMID>18425938</PMID>
  </reference>
  <reference>
    <citation>Luijten M, Veltman DJ, van den Brink W, Hester R, Field M, Smits M, Franken IH. Neurobiological substrate of smoking-related attentional bias. Neuroimage. 2011 Feb 1;54(3):2374-81. doi: 10.1016/j.neuroimage.2010.09.064. Epub 2010 Oct 13.</citation>
    <PMID>20932921</PMID>
  </reference>
  <reference>
    <citation>Suh JJ, Langleben DD, Ehrman RN, Hakun JG, Wang Z, Li Y, Busch SI, O'Brien CP, Childress AR. Low prefrontal perfusion linked to depression symptoms in methadone-maintained opiate-dependent patients. Drug Alcohol Depend. 2009 Jan 1;99(1-3):11-7. doi: 10.1016/j.drugalcdep.2008.06.007. Epub 2008 Jul 31.</citation>
    <PMID>18674871</PMID>
  </reference>
  <reference>
    <citation>Suh JJ, Pettinati HM, Kampman KM, O'Brien CP. Gender differences in predictors of treatment attrition with high dose naltrexone in cocaine and alcohol dependence. Am J Addict. 2008 Nov-Dec;17(6):463-8. doi: 10.1080/10550490802409074.</citation>
    <PMID>19034737</PMID>
  </reference>
  <reference>
    <citation>Zijlstra F, Booij J, van den Brink W, Franken IH. Striatal dopamine D2 receptor binding and dopamine release during cue-elicited craving in recently abstinent opiate-dependent males. Eur Neuropsychopharmacol. 2008 Apr;18(4):262-70.</citation>
    <PMID>18077142</PMID>
  </reference>
  <reference>
    <citation>Zijlstra F, Veltman DJ, Booij J, van den Brink W, Franken IH. Neurobiological substrates of cue-elicited craving and anhedonia in recently abstinent opioid-dependent males. Drug Alcohol Depend. 2009 Jan 1;99(1-3):183-92. doi: 10.1016/j.drugalcdep.2008.07.012. Epub 2008 Sep 26.</citation>
    <PMID>18823721</PMID>
  </reference>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2011</study_first_submitted>
  <study_first_submitted_qc>November 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2011</study_first_posted>
  <last_update_submitted>October 10, 2014</last_update_submitted>
  <last_update_submitted_qc>October 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>Wim van den Brink</investigator_full_name>
    <investigator_title>Prof. dr. W. van den Brink</investigator_title>
  </responsible_party>
  <keyword>opioid dependence</keyword>
  <keyword>heroin dependence</keyword>
  <keyword>extended release depot naltrexone</keyword>
  <keyword>functional Magnetic Resonance Imaging</keyword>
  <keyword>dopamine transporter</keyword>
  <keyword>Single Photon Emission Computed Tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
    <mesh_term>Heroin Dependence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

